Charite to Become 2nd Site for VISABL-VT

• Charite University Hospital in Berlin, Germany to join Imricor's VISABL-VT clinical trial
• Professor Dr Gerhard Hindricks, a world-renowned electrophysiologist, to oversee the project
• Charite is consistently ranked as a top 10 hospital worldwide

Imricor Medical Systems, Inc. (ASX: IMR) is excited to announce that the Charite University Hospital, in Berlin, Germany (Charite), will be the second site, worldwide, to join the VISABL-VT clinical trial. The Principal Investigator (PI) for VISABL-VT at Charite will be Professor Dr Felix Hohendanner, Senior Electrophysiologist and Head of Charite's Cardiac Catheterization Laboratories. Professor Dr Gerhard Hindricks, Head of Electrophysiology and Director of Cardiology at Charite, will oversee the entire project. Professor Hindricks is a worldwide thought leader in the field of electrophysiology and a past president of the European Heart Rhythm Association. Charite is consistently ranked in the top 10 hospitals worldwide, by Newsweek and U.S. News & World Report, and it houses more than half of the German Nobel Prize winners in medicine and physiology. Imricor's Chair and CEO, Steve Wedan, commented that the company is thrilled to have Germany's most prestigious hospital join the VISABL-VT trial, which they expect to change the world of electrophysiology forever. The electrophysiology team at Charite will also perform commercial atrial flutter ablations in the MRI lab as a part of their routine clinical work prior to, and concurrently with, the VISABL-VT trial. Atrial flutter ablations are expected to commence in Q1 2026.